Debby Wensink
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Debby Wensink has a total of 6 co-authors. Here are the top co-authors by number of shared publications:
- Janneke G. Langendonk
Department of Internal Medicine, Porphyria Expert Center Rotterdam, Center for Lysosomal and Metabolic Diseases Erasmus MC Rotterdam the Netherlands
4 shared publications - Margreet Wagenmakers
Center for Lysosomal and Metabolic Diseases, Erasmus MC University Medical Center Rotterdam The Netherlands
4 shared publications - J. H. Paul Wilson
Porphyria Expertcenter Rotterdam, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC, University Medical Center Rotterdam, Dr. Molewaterplein 40, 3015, GD, Rotterdam, the Netherlands
2 shared publications - Hongchao Qi
BHF Cardiovascular Epidemiology Unit, Department of Public Health and Primary Care University of Cambridge Cambridge UK
1 shared publication - Jane Hamilton Wilson
Porphyria Expertcenter Rotterdam, Center for Lysosomal and Metabolic Disease, Department of Internal Medicine, Erasmus MC Erasmus University Medical Center Rotterdam Rotterdam the Netherlands
1 shared publication - Sandra Coenen
Department of Gastroenterology and Hepatology, Erasmus Medical Center, 3015 GD Rotterdam, The Netherlands
1 shared publication
Latest Publications
- Open Access
- 28 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (4) , 445-452
Erythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide
Erythropoietic protoporphyria (EPP) patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. However, there is limited information on the psychosocial aspects of EPP. To investigate the clinical features and social aspects of living with EPP, before and during afamelanotide treatment in the Netherlands. A single‐center prospective longitudinal study of adult patients with EPP attending the Erasmus MC Rotterdam. Patients completed questionnaires, comprising demographic, clinical and social details, including two generic (DS‐14 and SF‐36) and a disease specific (EPP‐QoL) QoL questionnaires. 121 adult EPP patients were included. The educational level of EPP patients seemed higher compared to the Dutch population (36% vs. 30% high‐education, 42% vs. 37% middle‐education). At baseline 5% of the EPP patients were unemployed, none were unemployed during afamelanotide treatment. Full‐ and part‐time employment rate increased from 59.5% to 69.9% on afamelanotide treatment (p > 0.05). EPP‐QoL improved from 44% to 75% on afamelanotide treatment (p < 0.001). Type‐D personality was present in 27.4% of patients; their social inhibition scores improved significantly on afamelanotide treatment (p = 0.019). EPP patients scored low on the social functioning domain (SF‐36) compared to the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4; respectively), and improved during afamelanotide treatment (84.3 ± 20.9, p = 0.001). EPP has a significant negative impact on social aspects, with less employment despite a higher education level. Afamelanotide treatment improves quality of life, social functioning and possibly employment rate. It is important to recognize the impact of EPP on social life, although, more research is needed.
- 28 December 2022
- Published by Wiley in The Journal of Dermatology
- Vol. 50 (4) , 445-452
Open AccessErythropoietic protoporphyria in the Netherlands: Clinical features, psychosocial impact and the effect of afamelanotide
Erythropoietic protoporphyria (EPP) patients experience severe burning pain after light exposure, which results in a markedly reduced quality of life. However, there is limited information on the psychosocial aspects of EPP. To investigate the clinical features and social aspects of living with EPP, before and during afamelanotide treatment in the Netherlands. A single‐center prospective longitudinal study of adult patients with EPP attending the Erasmus MC Rotterdam. Patients completed questionnaires, comprising demographic, clinical and social details, including two generic (DS‐14 and SF‐36) and a disease specific (EPP‐QoL) QoL questionnaires. 121 adult EPP patients were included. The educational level of EPP patients seemed higher compared to the Dutch population (36% vs. 30% high‐education, 42% vs. 37% middle‐education). At baseline 5% of the EPP patients were unemployed, none were unemployed during afamelanotide treatment. Full‐ and part‐time employment rate increased from 59.5% to 69.9% on afamelanotide treatment (p > 0.05). EPP‐QoL improved from 44% to 75% on afamelanotide treatment (p < 0.001). Type‐D personality was present in 27.4% of patients; their social inhibition scores improved significantly on afamelanotide treatment (p = 0.019). EPP patients scored low on the social functioning domain (SF‐36) compared to the Dutch population (74.4 ± 27.3 vs. 84.0 ± 22.4; respectively), and improved during afamelanotide treatment (84.3 ± 20.9, p = 0.001). EPP has a significant negative impact on social aspects, with less employment despite a higher education level. Afamelanotide treatment improves quality of life, social functioning and possibly employment rate. It is important to recognize the impact of EPP on social life, although, more research is needed.
- Open Access
- 1 April 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54 (4) , 515-520
Liver involvement in patients with erythropoietic protoporphyria
- 1 April 2022
- Published by Elsevier in Digestive and Liver Disease
- Vol. 54 (4) , 515-520
Open AccessLiver involvement in patients with erythropoietic protoporphyria
- 2 January 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (3) , 215-220
Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study
- 2 January 2022
- Published by Elsevier in Molecular Genetics and Metabolism
- Vol. 135 (3) , 215-220
Objective light exposure measurements and circadian rhythm in patients with erythropoietic protoporphyria: A case-control study
- Open Access
- 1 February 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (2) , 151-160
Afamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain aft...
- 1 February 2021
- Published by Taylor & Francis in Expert Review of Clinical Pharmacology
- Vol. 14 (2) , 151-160
Open AccessAfamelanotide for prevention of phototoxicity in erythropoietic protoporphyria
In erythropoietic protoporphyria (EPP), an inherited disorder of heme biosynthesis, accumulation of protoporphyrin IX results in acute phototoxicity. EPP patients experience severe burning pain aft...